Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

NCT02077309 is registered in ClinicalTrials.gov with RWTH Aachen University as lead sponsor.

NCT NCT02077309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02077309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus
Lead sponsor
RWTH Aachen University
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2014
Completion date
November 30, 2015
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2 (t2dm), plaque morphology, vascular inflammation